Skip to content
Saunatica

Peptide

MOTS-C

  • Peptide
  • Metabolic & aging research
  • Not FDA-approved

MOTS-C is a mitochondrial peptide being studied for metabolism, physical function, bone biology, and aging. Intervention evidence comes from cells and rodents; no study has administered synthetic MOTS-C to people.

The basics

What is it?

MOTS-C is a naturally occurring peptide containing 16 amino acids. It is encoded by a short reading frame inside mitochondrial 12S ribosomal RNA and has been detected in both humans and rodents. Laboratory work suggests connections to cellular energy-stress signaling, including AMPK, but its direct molecular target is unknown. Measuring the MOTS-C a person's body naturally produces is different from administering synthetic MOTS-C.

Why it comes up

What are people interested in it for?

  • Glucose and lipid metabolism
  • Insulin-resistance and obesity research
  • Physical performance and muscle aging
  • Bone formation and bone loss
  • Vascular calcification and heart remodeling
  • Longevity research

These interests come from cell, rodent, and human observational research. None shows that administering synthetic MOTS-C improves these outcomes in people.

Evidence

What does the research show?

Animal evidence

High-fat-diet mouse studies reported less weight gain and liver-fat accumulation, along with changes in insulin-related measures. Other mouse work reported changes in muscle glucose uptake and less bone loss after ovary removal. One late-life experiment involving approximately 19 control and 18 treated male mice reported median lifespans of 912 and 970 days and maximum lifespans of 1,047 and 1,120 days, respectively, along with physical-performance findings. Other rodent studies examined bone remodeling and vascular calcification. FDA emphasizes that dose-response information is missing, the direct target is unknown, and the clinical meaning of these rodent findings is uncertain.

Human evidence

There are zero studies in which synthetic MOTS-C was administered to a person, zero human randomized controlled trials, and no human exposure, pharmacokinetic, clinical safety, or effectiveness data. Human studies have measured naturally circulating MOTS-C. For example, a 2021 study measured endogenous levels around exercise in 10 healthy sedentary young men but did not give them MOTS-C. Such measurements are physiology research, not treatment evidence.

Evidence grade

No formal GRADE assessment was found. Because there are no human administration studies, human efficacy evidence is absent and certainty is very low. This is an editorial description, not a published letter grade.

Unknowns and risks

What about safety?

FDA found no dedicated acute, repeat-dose, genotoxicity, reproductive or developmental, or carcinogenicity studies for MOTS-C free base or acetate, and there are no human safety studies. FAERS searches through March 9, 2025 found no reports, but incomplete voluntary reporting does not demonstrate safety. MOTS-C broke down rapidly in human blood in a laboratory experiment, and it is unknown whether administered peptide could maintain active concentrations. FDA also identified unresolved concerns about immune reactions, aggregation, impurities, identity, purity, endotoxins, and injectable-product manufacturing.

Regulatory status

Is it legal / FDA-approved?

  1. 1MOTS-C free base and acetate are not FDA-approved, have no applicable USP/NF drug-substance monograph, and are not components of an FDA-approved drug.
  2. 2Its former 503A Category 2 nomination was withdrawn. MOTS-C now appears under substances nominated but withdrawn, not the current Category 2 table, and it is not Category 1.
  3. 3MOTS-C is not on the final 503A Bulks List. The withdrawn nomination does not authorize compounding or grant Category 1 enforcement discretion.
  4. 4On July 23, 2026, PCAC reviews MOTS-C for obesity and osteoporosis. FDA staff proposes not adding either form. PCAC's recommendation is nonbinding, and FDA has not made a final decision.
  5. 5A "research use only" seller label is not FDA approval or authorization for human administration.
  6. 6MOTS-C is prohibited under anti-doping rules. That restriction is separate from FDA drug and compounding law.

A practical checklist

Questions to ask a licensed provider

  • Has synthetic MOTS-C ever been administered in a published human study?
  • Is the evidence being discussed interventional, or does it only measure natural MOTS-C levels?
  • What is known about short- and long-term human safety?
  • What is its current FDA and compounding status?
  • How would identity, sterility, endotoxins, aggregates, and impurities be checked?
  • What approved options have stronger human evidence for my goal?
  • How uncertain is the translation from the mouse findings to people?